Pediatric ANCA Associated-vasculitis

Pediatric ANCA Associated-vasculitis : Latest Clinical Review and Therapeutic Outcomes. A Retrospective Epidemiological Study on a French Cohort

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05383573

Acronym

PediANCA

Enrollment

500

Registered

2022-05-20

Start date

2022-01-01

Completion date

2022-12-31

Last updated

2022-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ANCA-Associated Vasculitis

Keywords

ANCA-Associated Vasculitis, Pediatric ANCA, Vasculitis

Brief summary

The incidence in pediatrics is very low (about 0.5 per million according to a French study) and therefore the data on the pathology very poor, especially on the therapeutic level. Without appropriate treatment, the mortality rate of the pathology is very high. Existing treatments are almost exclusively composed of immunomodulatory and/or immunosuppressive treatments. Complications related to pathology and iatrogeny are among the first causes of mortality from this pathology and deserve to be studied in order to be known and if possible avoided. The purpose of the study is to achieve a national comparison of clinical and therapeutic practices.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

1 Years to 17 Years

Inclusion criteria

* Minor subject (\<18 years old) * Diagnosis of ANCA vasculitis according to the international criteria for defining the pathology, GPA or MPA form between 2011 and 2020. * Subject (and/or his parental authority) who has not expressed, after being informed, his opposition to the reuse of his data for the purposes of this research.

Exclusion criteria

* Subject (or his parents) having expressed his (their) opposition to participating in the study * Patients with vasculitis has ANCA in the form of EGPA * Associated pathologies that cannot be related to the diagnosis of ANCA vasculitis and whose prognosis can lead to biases in the efficacy and/or complications related to treatments.

Design outcomes

Primary

Measure	Time frame
Retrospective study of clinical and therapeutic practices at the national level.	Files analysed retrospectively from January 01, 2011 to December 31, 2020 will be examined]

Countries

France

Contacts

Primary ContactAriane ZALOSZYC, MD

ariane.zaloszyc@chru-strasbourg.fr33 3 88 12 77 49

Backup ContactSaïd CHAYER, PhD, HDR

said.chayer@chru-strasbourg.fr

Outcome results